Almost 200 delegates from across the ECMC Network came together on 23 May 2019 for a chance to hear updates from the Programme Office, network with other ECMC members, and participate in some interesting discussions on complex trial design and patient referral.
Read our round up and gain access to the presentations from the day.
In January 2019 we held the seventh annual Junior Investigator Network Group (JING): Training the Next Generation event.
Over 100 people from across the ECMC network came to the two-day residential meeting in Cardiff, to learn more about early-phase trial design.
The PIONEER team in Glasgow has been working through the Combinations Alliance and having huge success in doing so. We caught up with them to find out more about their research.
Q. Describe the PIONEER trial and the anticipated patient benefit.
With CRUK and CSO joining NIHR as funders, the ECMC Programme Office will for the first time provide full support for the Paediatric Network through the recent recruitment of a dedicated Paediatric Network Manager. July saw the first Programme Office supported meeting of the ECMC Paediatric Network, bringing together both location and scientific theme leads from the network, alongside representatives from the Programme Office and CRUK, to discuss how they will work together over the next five years.
10 May saw the return of the Annual Network Meeting and, with 2017 marking the network’s 10th anniversary, it was indeed a very exciting and special event. Over 260 attendees from across the network joined us in the De Vere Grand Connaught Rooms in London.
The meeting began with a real appreciation of everything the ECMC network has done, and will continue to do in the years to come, with Sir Harpal Kumar (CRUK) and Dr Louise Wood (DoH) highlighting the network’s impressive achievements from the past decade, and trial spotlight talks from ICR and Edinburgh.
Describe the PATRIOT trial and the anticipated patient benefit.
The PATRIOT study is a multicentre ECMC Combinations Alliance Phase I study looking at the ATR inhibitor AZD6738 as a monotherapy in advanced solid tumours, and in combination with palliative radiotherapy. ATR inhibitors are a new class of anticancer therapy and there is significant evidence that they may provide tumour-selective radiosensitisation.